QLC1101 / Qilu Pharma - LARVOL DELTA

The Food Effect on Pharmacokinetics Study of QLC1101 in Healthy Subjects (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P1 trial

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation (clinicaltrials.gov) - P1/2 | N=240 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P1/2 trial • Solid Tumor • KRAS

Safety and efficacy of QLC1101 in KRAS G12D-mutant advanced solid tumors: results from a phase 1a study [WITHDRAWN] (AACR 2025) - "Abstract is embargoed at this time."

Clinical • Metastases • P1 data • Oncology • Solid Tumor • KRAS

A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=250 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

Metastases • Monotherapy • New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS